SSTR2 and pituitary gland adenoma: The development of SSAs that recognize and activate SSTR3 is a potentially promising strategy, due to the fact that (1) NFPAs mainly express SSTR3, which is also maintained after radiotherapy [3] and (2) the response of pituitary adenomas to SSAs depends on the expression of specific SSTR subtypes, as seen for SSTR2 in GH-secreting adenomas [25].